ClinicalTrials.gg
RecruitingNCT04578652Updated Oct 23, 2026

Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance

A Phase 3 interventional study of Metformin 850 mg oral tablet bid and Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX. in Obesity, Childhood and Insulin Resistance, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by University of Alberta · Phase 3, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.
Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Pediatric Obesity with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Pediatric Obesity · Canada.

Planned enrollment
19th of 40
90 · median 73
Started
2021
with 5 others
Phase 3
Only one
of the 51
Registered
38th of 51
by date
Lead sponsor
9 of 51
University of Alberta

Among the 51 studies in Pediatric Obesity with a site in Canada, this one is the 19th largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2021, is the only one in phase 3, and was the 38th registered.

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

Browse Pediatric Obesity studies →

Open to participants now

7 of the 51 studies in Pediatric Obesity with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Pediatric Obesity with a site in Canada, or all of them as a file.
02

Study summary

This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance [IR]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function.

Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM.

.

03

Conditions studied

  • Obesity, Childhood
  • Insulin Resistance

Keywords

  • Dietary fiber
  • Metformin
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 12-18 years
  2. percentile > 95% for age/sex;
  3. Total weight fluctuation over past 6 months \< 10%;
  4. HOMA-IR > 3.16;
  5. FH of T2DM (first or second-degree relative).

Exclusion criteria

Exclusion Criteria:

  1. Current use of insulin or diagnosis of T2DM;
  2. Systolic or diastolic blood pressure (BP) > 99th percentile for age and sex;
  3. Acute infectious or inflammatory condition over the preceding 1 month; hospitalization > 48 hrs;
  4. History of chronic disease such as inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders;
  5. Active ;
  6. Concomitant use of medication/ drug known to affect body weight in the past year;
  7. Antibiotic use in past 60 days; probiotic and/or prebiotic supplements use in the past 30 days; use of lipid-lowering and anti-inflammatory medication.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    MET

    MET (850 mg po bid - standard of care) + Fiber placebo daily

    Drug: Metformin 850 mg oral tablet bid

  • Active comparator
    FIBER

    Fiber supplementation \[35g fiber daily\] + MET placebo po bid

    Dietary Supplement: Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.

  • Experimental
    FIBER + MET

    Fiber supplementation \[35g fiber daily\] + MET 850 mg po bid

    Drug: Metformin 850 mg oral tablet bid · Dietary Supplement: Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.

Interventions

  • DrugMetformin 850 mg oral tablet bid

    MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).

  • Dietary supplementSupplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.

    The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.

06

What researchers measure

Primary outcomes

  1. Changes in HOMA-IR

    Change in HOMA-IR value

    Time frame: Baseline, 6, and 12 months

Secondary outcomes

  1. Changes in body weight

    Body weight measured in kg

    Time frame: Baseline, 6, and 12 months

  2. Changes in body mass index (BMI)

    BMI percentile and z-score according to age and sex will be estimated

    Time frame: Baseline, 6, and 12 months

  3. Changes in body composition

    Body density using air-displacement plethysmography will be assessed to estimate fat mass and fat-free mass.

    Time frame: Baseline, 6, and 12 months

  4. Changes in inflammation

    Markers of inflammation that will be measured are: high-sensitivity C-reactive protein, interleukin, tumor necrosis factor-alpha)

    Time frame: Baseline, 6, and 12 months

  5. Changes in metabolic function

    The markers of metabolic function that will be measured are: fasting glucose, lipids (total, high and low density lipoprotein cholesterol; triglycerides), and oral glucose tolerance test.

    Time frame: Baseline, 6, and 12 months

  6. Changes in satiety hormones

    Markers of satiety that will be measured are: acylated ghrelin, peptide tyrosine tyrosine, GLP-1, leptin, and adiponectin.

    Time frame: Baseline, 6, and 12 months

  7. Changes in quality of life

    Quality of life will be measured by the a questionnaire

    Time frame: Baseline, 6, and 12 months

  8. Changes in perceived hunger and satiety

    Perceived hunger and satiety will be assessed by a questionnaire

    Time frame: Baseline, 6, and 12 months

  9. Changes in gut microbiota composition

    Fecal microbiota composition will be characterized by 16S rRNA gene amplicons sequencing using taxonomic and non-taxonomic based approaches.

    Time frame: Baseline, 6, and 12 months

  10. Changes in gut microbiome functions

    Fecal microbiome functions will be assessed through whole metagenomic sequencing, stool SCFAs and bile acids, and plasma metabolomics.

    Time frame: Baseline, 6, and 12 months

  11. Changes in intestinal barrier integrity

    Plasma lipopolysaccharide-binding protein and fecal calprotectin will be determined as measures of gut barrier integrity

    Time frame: Baseline, 6, and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Fahim SM, Huey SL, Palma Molina XE, Agarwal N, Ridwan P, Ji N, Kibbee M, Kuriyan R, Finkelstein JL, Mehta S. Gut microbiome-based interventions for the management of obesity in children and adolescents aged up to 19 years. Cochrane Database Syst Rev. 2025 Jul 10;7(7):CD015875. doi: 10.1002/14651858.CD015875. PubMed 40637175 ↗
  • Deehan EC, Colin-Ramirez E, Triador L, Madsen KL, Prado CM, Field CJ, Ball GDC, Tan Q, Orsso C, Dinu I, Pakseresht M, Rubin D, Sharma AM, Tun H, Walter J, Newgard CB, Freemark M, Wine E, Haqq AM. Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial. Trials. 2021 Feb 17;22(1):148. doi: 10.1186/s13063-021-05060-8. PubMed 33596993 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2021 (actual). Primary completion is estimated for Feb 2027, 64 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2026 → Feb 2027 and completion Sep 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2020
First posted
Oct 8, 2020
StartActual
Oct 22, 2021
Primary completionEst.
Feb 2027was Sep 2026
CompletionEst.
Feb 2027was Sep 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Feb 2027
Oct 23, 2026
Study completion
Sep 2026→Feb 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Sep 2026→Feb 2027
    Study completion Sep 2026→Feb 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04578652
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Oct 22, 2021
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Andrea M Haqq, MD, MHS
Contact
haqq@ualberta.ca
780-492-0015
Andrea M Haqq, MD, MHS
principal investigator · University of Alberta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion